Next Catalyst FDA itself - Market itself
What we know is that ONCY chose the wrong check point inhibitor. The question remains as to if other checkpoint inhibitors would work. To know this, another 5 years would need to be wasted to find out.
Bottom line, ONCY should have just gone with IND-213 and pale would have been registered now.
Well, the checkpoint collaborators wasted our time here. They pushed for Bracelet-1, paid nothing (no licensing deal)....
Back to business, chemeo + virus is the simple combo to go. It is a cheap option, potentially undercutting checkpoint inhibitors as an alternative competitive option. So the number crunching needs to be done. The addressable market seems bigger now, much bigger now.
FDA will confirm trial design element by granting accelerated approval status. We shave -18 months. Also two arm studies is fast and simple we shaved another 6 months.
Assuming recruitment starts in Q1 2024, by Q4 2024 we will have a registered/approved drug.
Cash need could be met already with Adlai Nortye licensing. We only need another 60 millions, which Aldai should mostly pay. So, are nearing the end of dilution. The market itself will reward SP.